|
Synonyms: IONIS-FB-LRX | RO-7434656 | RO7434656
Compound class:
Nucleic acid
Comment: Sefaxersen (IONIS-FB-LRX) is a liver-directed antisense oligonucleotide (ASO) that reduces synthesis of complement factor B protein by binding to the mRNA transcript. The molecule is N-acetylgalactosamine (GalNAc) modified to enhance hepatic delivery via binding to liver-expressed asialoglycoprotein receptors (ASGRs).
Full sequence is: all-P-ambo-5'-O-(28-[(2-acetamido-2-deoxy-β-D - galactopyranosyl)oxy]-16,16-bis{[3-({6-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]hexyl}amino)-3-oxopropoxy]methyl}-1-hydroxy-1,10,14,21-tetraoxo-2,18-dioxa-9,15,22-triaza-1λ5-phosphaoctacosan-1-yl)-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylcytidine |
| No information available. |
Summary of Clinical Use ![]() |
| Sefaxersen (IONIS-FB-LRX) was progessed as a clinical candidate for potential to treat IgA nephropathy (IgAN) and macular degenerative conditions. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03446144 | Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) | Phase 2 Interventional | Ionis Pharmaceuticals, Inc. | ||
| NCT04014335 | A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy | Phase 2 Interventional | Ionis Pharmaceuticals, Inc. | ||
| NCT03815825 | GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) | Phase 2 Interventional | Ionis Pharmaceuticals, Inc. | ||
| NCT05797610 | A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression | Phase 3 Interventional | Hoffmann-La Roche | ||